Last updated: May 20, 2026
CUPRIMINE is an oral copper-chelating drug using trientine hydrochloride as the active ingredient for Wilson disease. Public, regulator-linked and trial-linked updates are required for a complete, accurate clinical-trials and market-projection brief, but no reliable, current source set is available in this workspace to substantiate: (1) the latest enrolled/active trials, (2) trial readouts and timelines, (3) current sales/revenue benchmarks, or (4) Orange Book exclusivity and patent expiration/generic entry dates by label strength.
No complete and accurate response can be produced without verifiable clinical, regulatory, and commercial inputs.
What clinical trials are ongoing for CUPRIMINE (trientine hydrochloride) and what are the latest updates?
A complete clinical trials update requires current trial-state data (active vs recruiting vs completed), study identifiers, key inclusion criteria (adult vs pediatric, baseline copper/ceruloplasmin), endpoints (24-hour urinary copper, normalized liver enzymes), and the most recent posting date.
No verifiable trial dataset is available in this workspace.
Which registrational or pivotal trials underpin CUPRIMINE’s current indication?
A credible summary needs named registrational studies, dosing regimens, comparator arms (if any), and FDA-label mapping.
No verifiable study list is available in this workspace.
Are there new formulations, dosing changes, or pediatric extensions in CUPRIMINE’s pipeline?
A pipeline update must enumerate sponsor, phase, formulation type (e.g., capsule vs tablet vs oral solution), and whether it targets pediatric dosing, adherence, or bioavailability.
No verifiable pipeline information is available in this workspace.
What market share and sales does CUPRIMINE have in Wilson disease, and how is the market changing?
A market analysis needs at minimum: global and US revenue estimates for Wilson disease chelators; share by brand; pricing and net sales; and mix effects (adult vs pediatric, US vs ex-US). CUPRIMINE’s performance also depends on competitive dynamics versus penicillamine and alternative trientine brands and generics.
No reliable sales or share dataset is available in this workspace.
How does CUPRIMINE compare with competitors for Wilson disease treatment (penicillamine, zinc, other trientine brands)?
Comparison requires current label details, dosing schedules, and payer dynamics by product. Market-facing projections depend on switching patterns and tolerability profile.
No verifiable competitor dataset is available in this workspace.
What drives demand for CUPRIMINE (diagnosis rates, treatment guidelines, payer coverage)?
Demand projections require epidemiology and diagnosed-prevalence trends plus guideline-based prescribing data.
No verifiable demand inputs are available in this workspace.
When does CUPRIMINE lose exclusivity, and what are the key patent expiration dates?
Exclusivity timelines need the US FDA Orange Book listing status and the governing patent/exclusivity periods (drug substance, drug product, and method-of-use, plus any Hatch-Waxman or orphan exclusivity if applicable). Market projections must map patent dates to expected generic/authorized generic entry.
No Orange Book patent/exclusivity listing data is available in this workspace.
What patents protect CUPRIMINE in the US (drug substance, drug product, and methods)?
A patent estate analysis requires patent numbers, titles/claims, assignees, filing dates, priority dates, expiration dates, and relevant continuation or terminal disclaimers.
No patent estate data is available in this workspace.
How many patents are listed for CUPRIMINE in the Orange Book, and what do they cover?
This requires the exact number of Orange Book listings by strength and dosage form, and coverage mapping to specific formulation or dosing instructions.
No Orange Book listing data is available in this workspace.
Are there Paragraph IV challenges for CUPRIMINE, and which companies are targeting it?
A Paragraph IV section requires: ANDA filer identities, active litigation dates, settlement announcements, and FDA approval timing constraints.
No ANDA/Paragraph IV litigation record is available in this workspace.
What patent litigation affects CUPRIMINE right now (case filings, stays, settlements)?
A litigation update requires court docket facts: filing dates, claims asserted, venue, brands involved, and any settlement-triggered entry dates.
No litigation record is available in this workspace.
What generic entry risks exist for CUPRIMINE (US) and how fast could generics capture share?
A speed-to-capture model needs: expected launch dates (from exclusivity/patent expiry), number of challengers, label/BE requirements, and typical payer adoption curves.
No exclusivity/patent expiry or ANDA launch timing is available in this workspace.
How does CUPRIMINE’s strength and dosage form affect generic substitution?
Generic risk differs by dosage form and strength-level approvals.
No product-specific substitution data is available in this workspace.
What manufacturing and formulation/IP barriers could delay generic approval?
This requires identification of formulation patents and manufacturing-process claims.
No formulation/manufacturing IP data is available in this workspace.
What is CUPRIMINE’s FDA regulatory status (NDA, approvals, REMS, labeling updates)?
A regulatory status section requires the NDA number, approval history, listed strengths and dosage forms, any REMS requirement, and labeling changes by date.
No FDA regulatory listing data is available in this workspace.
What FDA pathways have been used historically for CUPRIMINE (505(b)(1), 505(j), etc.)?
This depends on the application history and regulatory action dates.
No application pathway data is available in this workspace.
How strong is the overall IP and regulatory moat for CUPRIMINE versus generics and authorized generics?
Moat strength depends on patent breadth (claims that cover therapeutic use vs formulation), remaining term, and enforcement activity.
No patent/Orange Book data is available in this workspace.
What is the likelihood that CUPRIMINE faces biosimilar-like replacement risk?
Trientine is a small-molecule, so the biosimilar framework is not applicable, but substitution risk is still driven by small-molecule generic entry and potential authorized generics.
No exclusivity/patent data is available in this workspace.
Key takeaways
- CUPRIMINE is a trientine hydrochloride chelator used for Wilson disease, but a complete clinical trials update, market analysis, and exclusivity-to-generic entry projection cannot be produced with verifiable sources in this workspace.
- A full analysis requires FDA Orange Book listings (patents and exclusivity), ANDA/Paragraph IV and litigation status, and current clinical-trial postings plus sales benchmarks. None of these data sources are available here.
FAQs
- Is CUPRIMINE covered under any US orphan exclusivity or other statutory exclusivity protections for Wilson disease?
- What are the main therapeutic endpoints used in trientine clinical studies (urinary copper, hepatic copper, liver biochemistry)?
- Which companies currently manufacture trientine hydrochloride products competing with CUPRIMINE in the US?
- How do tolerability and adherence factors affect switching between trientine, penicillamine, and zinc therapies?
- What Orange Book listings are typically most relevant for generic applicants seeking to launch a trientine product?
References (APA)
-
